vs

Side-by-side financial comparison of PROCEPT BioRobotics Corp (PRCT) and RICHTECH ROBOTICS INC. (RR). Click either name above to swap in a different company.

PROCEPT BioRobotics Corp is the larger business by last-quarter revenue ($83.1M vs $1.1M, roughly 72.5× RICHTECH ROBOTICS INC.). PROCEPT BioRobotics Corp runs the higher net margin — -38.1% vs -732.5%, a 694.5% gap on every dollar of revenue. On growth, PROCEPT BioRobotics Corp posted the faster year-over-year revenue change (20.2% vs -8.8%).

PROCEPT BioRobotics Corp is a medical tech firm developing and commercializing robotic surgical solutions for urological care. Its flagship AquaBeam system provides image-guided minimally invasive therapy for benign prostatic hyperplasia, serving providers and patients across North America, Europe and global markets.

Richtech Robotics Inc. develops, manufactures and sells AI-powered commercial service robots, including food delivery, intelligent cleaning and hospitality automation solutions. It serves catering, retail, hotel and healthcare clients across North America, Asia Pacific and European markets.

PRCT vs RR — Head-to-Head

Bigger by revenue
PRCT
PRCT
72.5× larger
PRCT
$83.1M
$1.1M
RR
Growing faster (revenue YoY)
PRCT
PRCT
+28.9% gap
PRCT
20.2%
-8.8%
RR
Higher net margin
PRCT
PRCT
694.5% more per $
PRCT
-38.1%
-732.5%
RR

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
PRCT
PRCT
RR
RR
Revenue
$83.1M
$1.1M
Net Profit
$-31.6M
$-8.4M
Gross Margin
64.9%
52.3%
Operating Margin
-4.1%
-1029.6%
Net Margin
-38.1%
-732.5%
Revenue YoY
20.2%
-8.8%
Net Profit YoY
-27.9%
-136.8%
EPS (diluted)
$-0.56
$-0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PRCT
PRCT
RR
RR
Q1 26
$83.1M
Q4 25
$76.4M
$1.1M
Q3 25
$83.3M
Q2 25
$79.2M
Q1 25
$69.2M
Q4 24
$68.2M
Q3 24
$58.4M
Q2 24
$53.4M
Net Profit
PRCT
PRCT
RR
RR
Q1 26
$-31.6M
Q4 25
$-29.8M
$-8.4M
Q3 25
$-21.4M
Q2 25
$-19.6M
Q1 25
$-24.7M
Q4 24
$-18.9M
Q3 24
$-21.0M
Q2 24
$-25.6M
Gross Margin
PRCT
PRCT
RR
RR
Q1 26
64.9%
Q4 25
60.6%
52.3%
Q3 25
64.8%
Q2 25
65.4%
Q1 25
63.9%
Q4 24
64.0%
Q3 24
63.2%
Q2 24
59.0%
Operating Margin
PRCT
PRCT
RR
RR
Q1 26
-4.1%
Q4 25
-40.6%
-1029.6%
Q3 25
-27.8%
Q2 25
-28.0%
Q1 25
-39.7%
Q4 24
-28.9%
Q3 24
-38.4%
Q2 24
-50.3%
Net Margin
PRCT
PRCT
RR
RR
Q1 26
-38.1%
Q4 25
-39.1%
-732.5%
Q3 25
-25.7%
Q2 25
-24.7%
Q1 25
-35.8%
Q4 24
-27.6%
Q3 24
-35.9%
Q2 24
-48.0%
EPS (diluted)
PRCT
PRCT
RR
RR
Q1 26
$-0.56
Q4 25
$-0.54
$-0.04
Q3 25
$-0.38
Q2 25
$-0.35
Q1 25
$-0.45
Q4 24
$-0.34
Q3 24
$-0.40
Q2 24
$-0.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PRCT
PRCT
RR
RR
Cash + ST InvestmentsLiquidity on hand
$245.6M
$328.5M
Total DebtLower is stronger
$51.7M
Stockholders' EquityBook value
$347.7M
$339.7M
Total Assets
$487.1M
$349.4M
Debt / EquityLower = less leverage
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PRCT
PRCT
RR
RR
Q1 26
$245.6M
Q4 25
$286.5M
$328.5M
Q3 25
$294.3M
Q2 25
$302.7M
Q1 25
$316.2M
Q4 24
$333.7M
Q3 24
$196.8M
Q2 24
$214.1M
Total Debt
PRCT
PRCT
RR
RR
Q1 26
$51.7M
Q4 25
$51.6M
Q3 25
$51.6M
Q2 25
$51.5M
Q1 25
$51.5M
Q4 24
$51.5M
Q3 24
$51.4M
Q2 24
$51.4M
Stockholders' Equity
PRCT
PRCT
RR
RR
Q1 26
$347.7M
Q4 25
$365.9M
$339.7M
Q3 25
$380.3M
Q2 25
$385.8M
Q1 25
$389.2M
Q4 24
$402.2M
Q3 24
$241.2M
Q2 24
$251.8M
Total Assets
PRCT
PRCT
RR
RR
Q1 26
$487.1M
Q4 25
$508.1M
$349.4M
Q3 25
$511.5M
Q2 25
$513.1M
Q1 25
$519.4M
Q4 24
$534.0M
Q3 24
$374.1M
Q2 24
$374.4M
Debt / Equity
PRCT
PRCT
RR
RR
Q1 26
0.15×
Q4 25
0.14×
Q3 25
0.14×
Q2 25
0.13×
Q1 25
0.13×
Q4 24
0.13×
Q3 24
0.21×
Q2 24
0.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PRCT
PRCT
RR
RR
Operating Cash FlowLast quarter
$-1.6M
Free Cash FlowOCF − Capex
$-1.7M
FCF MarginFCF / Revenue
-146.1%
Capex IntensityCapex / Revenue
6.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PRCT
PRCT
RR
RR
Q1 26
Q4 25
$-10.3M
$-1.6M
Q3 25
$-6.6M
Q2 25
$-15.0M
Q1 25
$-17.0M
Q4 24
$-32.4M
Q3 24
$-18.8M
Q2 24
$-15.7M
Free Cash Flow
PRCT
PRCT
RR
RR
Q1 26
Q4 25
$-12.2M
$-1.7M
Q3 25
$-9.5M
Q2 25
$-17.8M
Q1 25
$-18.8M
Q4 24
$-33.6M
Q3 24
$-19.0M
Q2 24
$-16.8M
FCF Margin
PRCT
PRCT
RR
RR
Q1 26
Q4 25
-15.9%
-146.1%
Q3 25
-11.4%
Q2 25
-22.5%
Q1 25
-27.2%
Q4 24
-49.2%
Q3 24
-32.6%
Q2 24
-31.4%
Capex Intensity
PRCT
PRCT
RR
RR
Q1 26
Q4 25
2.4%
6.2%
Q3 25
3.4%
Q2 25
3.5%
Q1 25
2.7%
Q4 24
1.7%
Q3 24
0.4%
Q2 24
2.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PRCT
PRCT

Handpieces and other consumables$43.0M52%
System sales and rentals$23.4M28%
Other$11.1M13%
Service$5.6M7%

RR
RR

Segment breakdown not available.

Related Comparisons